Article

Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial

2020-10-23

Abstract excerpt

The antiparasitic drug nitazoxanide is widely available and exerts broad-spectrum antiviral activity in vitro . However, there is no evidence of its impact on SARS-CoV-2 infection. In a multicenter, randomized, double-blind, placebo-controlled trial, adult patients who presented up to 3 days after onset of Covid-19 symptoms (dry cough, fever, and/or fatigue) were enrolled. After confirmation of SARS-CoV2 infecti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0f595ce3-f459-56e0-8b81-b902d6e6c8f9
DOI: 10.1101/2020.10.21.20217208

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trialDOI 10.1101/2020.10.21.20217208Read

Favipiravir and/or Nitazoxanide: a randomized, double-blind, 2x2 design, placebo-controlled trial of early therapy in COVID-19 (FANTAZE).Semantic proximity Read

Efficacy and Safety of AYUSH-64 in COVID-19: A Systematic Review and Meta-AnalysisSemantic proximity Read

Comparative efficacy and safety of current drugs against COVID-19: A systematic review and network meta-analysisSemantic proximity Read

REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 OutpatientsSemantic proximity Read

Effect of Paxlovid Treatment During Acute Covid-19 on Long Covid Onset: An EHR-Based Target Trial Emulation from the N3C and RECOVER ConsortiaSemantic proximity Read

Bromhexine, for Post Exposure COVID-19 Prophylaxis: A Randomized, Double-Blind, Placebo Control TrialSemantic proximity Read

Hydroxychloroquine with or Without Azithromycin for Treatment of Early SARS-CoV-2 Infection Among High-Risk Outpatient Adults: A Randomized Clinical TrialSemantic proximity Read

There Was No New Needle in the COVID Therapeutic Haystack A COVID-19 Therapeutics AnalysisSemantic proximity Read

Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2: A single-center large observational studySemantic proximity Read

Bromhexine, for post exposure COVID-19 prophylaxis: A Randomized, Double-Blind, Placebo Control TrialSemantic proximity Read

Prevalence use of nonsteroidal anti-inflammatory drugs in the general population with COVID-19 and associated COVID-19 risk, hospitalization, severity, death, and safety outcomes: A systematic review and meta-analysisSemantic proximity Read

Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trialSemantic proximity Read